VEGF Gene Transfer for Critical Limb Ischemia
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 6
研究概览
简要总结
The purpose of this gene therapy study is to evaluate the safety and efficacy of intramuscular gene transfer using Vascular Endothelial Growth Factor (VEGF) or placebo in patients with moderate to high-risk Critical Limb Ischemia (a condition in which there is poor blood circulation in the leg). This trial will assess whether VEGF improves rest pain and/or heals ulcers in the legs of patients with peripheral artery disease (blockages in leg arteries.)
VEGF is DNA, or genetic material that will be injected into the leg muscles on three separate occasions, each 2 weeks apart. Once the DNA is in the leg, it directs the cells of the artery wall to increase its production of VEGF, which has been shown to cause new blood vessels to grow. This experimental therapy is designed to grow new blood vessels around blockages in the leg arteries.
The total length of participation in this study is approximately 1 year and will require approximately 8 clinic visits within that year. Following enrollment in the study, testing may be done for cancer screening, blood work, physical exams, vascular testing and eye exams. There is no charge for any testing or office visits required by the study.
This study has been approved by the Food and Drug Administration (FDA).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be at least 21 years old
- •Have critical limb ischemia
- •Have severe blockages in at least one artery in the affected leg as demonstrated by an angiogram
- •Have nonhealing leg ulcers and/ or have severe rest pain secondary to a severely decreased blood flow
- •Agree to participate in follow-up.
排除标准
- •Have any evidence of malignant neoplasms (other than non-melanoma skin cancer or in situ carcinoma) within the last 5 years
- •Be pregnant or lactating
- •Have a history of alcohol or drug abuse within 3 months of screening
- •Have advanced (Rutherford Category 6) critical limb ischemia, characterized by extensive tissue loss or gangrene
- •Have osteomyelitis
- •Have undergone successful aortic or lower extremity surgery, angioplasty, or lumbar sympathectomy within the 2 months preceding screening
- •Be a suitable candidate for surgical or endovascular revascularization in the limb in which treatment is proposed
- •Subjects in whom arterial insufficiency in the lower extremity is the result of a non-atherosclerotic disorder